MedTrace Logo

Safety And PK Study Of CVX-060 In Patients With Advanced Solid Tumors

NCT00879684 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2015-01-26

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the safety and tolerability of CVX-060 in patients with advanced solid tumors.

Conditions

Interventions

BIOLOGICAL

CVX-060

Weekly, intravenous dose

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2011-04-30
Completion
2011-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00879684 on ClinicalTrials.gov